Current Protein Identity:Q16740 New Search
Main Difference Dimensions in This Set
Different construct Different mutation/modification Different assembly state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics

Difference tags compare only the current result set; every original PDB and assembly record remains separate.

Related-Structure Differences

Each row represents one biological assembly in one PDB entry; multiple monomers of the same protein are listed separately.

PDB Entry Assembly / Oligomeric State Construct Mutations and Modifications Ligands, Ions and Non-polymers Experimental Method Experimental Conditions Structure Quality
1TG6 Crystallography and mutagenesis point to an essential role for the N-terminus of human mitochondrial ClpP Deposited 2004-05-28 Assembly 1 Protein homooligomer Homooligomer;Protein × 7 PDB declaration: heptameric(7) Consistent with protein count
Chain A 1–277(277 aa)
Chain B 1–277(277 aa)
Chain C 1–277(277 aa)
Chain D 1–277(277 aa)
Chain E 1–277(277 aa)
Chain F 1–277(277 aa)
Chain G 1–277(277 aa)
Not recorded DIO 1,4-DIETHYLENE DIOXIDE × 6 EDO 1,2-ETHANEDIOL × 8 GOL GLYCEROL × 6 FME N-FORMYLMETHIONINE × 7 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;100 mM MES pH 6.5, 10 % (V/V) dioxane, 10% glycerol, 1.5-1.8 M (NH4)2SO4 with 20% ethylene glycol, VAPOR DIFFUSION, HANGING DROP
Resolution 2.10 Å R-free 0.262
1TG6 Crystallography and mutagenesis point to an essential role for the N-terminus of human mitochondrial ClpP Deposited 2004-05-28 Assembly 2 Protein homooligomer Homooligomer;Protein × 14 PDB declaration: tetradecameric(14) Consistent with protein count
Chain A 1–277(277 aa)
Chain B 1–277(277 aa)
Chain C 1–277(277 aa)
Chain D 1–277(277 aa)
Chain E 1–277(277 aa)
Chain F 1–277(277 aa)
Chain G 1–277(277 aa)
Not recorded DIO 1,4-DIETHYLENE DIOXIDE × 12 EDO 1,2-ETHANEDIOL × 16 GOL GLYCEROL × 12 FME N-FORMYLMETHIONINE × 14 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;100 mM MES pH 6.5, 10 % (V/V) dioxane, 10% glycerol, 1.5-1.8 M (NH4)2SO4 with 20% ethylene glycol, VAPOR DIFFUSION, HANGING DROP
Resolution 2.10 Å R-free 0.262
6BBA Crystal structure of human mitochondrial ClpP complex with acyldepsipeptide ADEP-28 Deposited 2017-10-17 Assembly 1 Protein heterocomplex Heteromer;Protein × 14 PDB declaration: tetradecameric(14) Consistent with protein count
Chain A 58–277(220 aa) Fragment:residues 58-277
Chain B 58–277(220 aa) Fragment:residues 58-277
Chain C 58–277(220 aa) Fragment:residues 58-277
Chain D 58–277(220 aa) Fragment:residues 58-277
Chain E 58–277(220 aa) Fragment:residues 58-277
Chain F 58–277(220 aa) Fragment:residues 58-277
Chain G 58–277(220 aa) Fragment:residues 58-277
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 4.6;294 K;0.1 M sodium acetate trihydrate pH 4.6, 4% w/v polyethylene glycol 4,000
Resolution 2.80 Å R-free 0.235
6DL7 Human mitochondrial ClpP in complex with ONC201 (TIC10) Deposited 2018-05-31 Assembly 1 Protein homooligomer Homooligomer;Protein × 7 PDB declaration: heptameric(7) Consistent with protein count
Chain A 58–277(220 aa)
Chain B 58–277(220 aa)
Chain C 58–277(220 aa)
Chain D 58–277(220 aa)
Chain E 58–277(220 aa)
Chain F 58–277(220 aa)
Chain G 58–277(220 aa)
Not recorded ONC 7-benzyl-4-[(2-methylphenyl)methyl]-6,7,8,9-tetrahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one × 7 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 5.2;277 K;5%(w/v) PEG 4,000, 100mM KCl, 100mM NaAc (pH5.2)
Resolution 2.00 Å R-free 0.262
6H23 Crystal structure of the hClpP Y118A mutant with an activating small molecule Deposited 2018-07-13 Assembly 1 Protein homooligomer Homooligomer;Protein × 14 PDB declaration: tetradecameric(14) Consistent with protein count
Chain A 57–277(221 aa)
Chain B 57–277(221 aa)
Chain C 57–277(221 aa)
Chain D 57–277(221 aa)
Chain E 57–277(221 aa)
Chain F 57–277(221 aa)
Chain G 57–277(221 aa)
Chain H 57–277(221 aa)
Chain I 57–277(221 aa)
Chain J 57–277(221 aa)
Chain K 57–277(221 aa)
Chain L 57–277(221 aa)
Chain M 57–277(221 aa)
Chain N 57–277(221 aa)
Mutation:Y118A Mutation:Y118A Mutation:Y118A Mutation:Y118A Mutation:Y118A Mutation:Y118A Mutation:Y118A Mutation:Y118A Mutation:Y118A Mutation:Y118A Mutation:Y118A Mutation:Y118A Mutation:Y118A Mutation:Y118A FJT ~{N}-(1,3-benzodioxol-5-ylmethyl)-5-[(2-chloranyl-4-fluoranyl-phenyl)methyl]-1,3,4-oxadiazole-2-carboxamide × 14 EDO 1,2-ETHANEDIOL × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;293 K;magnesium chloride, MES, PEG4000
Resolution 3.09 Å R-free 0.261
7UVM Crystal structure of human ClpP protease in complex with TR-27 Deposited 2022-05-02 Assembly 1 Protein homooligomer Homooligomer;Protein × 14 PDB declaration: tetradecameric(14) Consistent with protein count
Chain A 58–277(220 aa)
Chain B 58–277(220 aa)
Chain C 58–277(220 aa)
Chain D 58–277(220 aa)
Chain E 58–277(220 aa)
Chain F 58–277(220 aa)
Chain G 58–277(220 aa)
Not recorded OX0 (10R)-4-[(4-chlorophenyl)methyl]-7-[(3-ethynylphenyl)methyl]-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one × 14 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6 to 5.2, 5 % PEG 4000
Resolution 2.19 Å R-free 0.237
7UVN Crystal structure of human ClpP protease in complex with TR-57 Deposited 2022-05-02 Assembly 1 Protein homooligomer Homooligomer;Protein × 14 PDB declaration: tetradecameric(14) Consistent with protein count
Chain A 58–277(220 aa)
Chain B 58–277(220 aa)
Chain C 58–277(220 aa)
Chain D 58–277(220 aa)
Chain E 58–277(220 aa)
Chain F 58–277(220 aa)
Chain G 58–277(220 aa)
Not recorded P3O 3-({3-[(4-chlorophenyl)methyl]-1-methyl-2,4-dioxo-1,3,4,5,7,8-hexahydropyrido[4,3-d]pyrimidin-6(2H)-yl}methyl)benzonitrile × 14 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate, pH 4.6 to 5.2, 5 % PEG 4000
Resolution 3.11 Å R-free 0.283
7UVR Crystal structure of human ClpP protease in complex with TR-65 Deposited 2022-05-02 Assembly 1 Protein homooligomer Homooligomer;Protein × 14 PDB declaration: tetradecameric(14) Consistent with protein count
Chain A 58–277(220 aa)
Chain B 58–277(220 aa)
Chain C 58–277(220 aa)
Chain D 58–277(220 aa)
Chain E 58–277(220 aa)
Chain F 58–277(220 aa)
Chain G 58–277(220 aa)
Not recorded PJF 3-{[(10R)-4-[(4-chlorophenyl)methyl]-5-oxo-1,2,4,5,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-7(6H)-yl]methyl}benzonitrile × 14 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6 to 5.2, 5% PEG 4000
Resolution 2.86 Å R-free 0.253
7UVU Crystal structure of human ClpP protease in complex with TR-107 Deposited 2022-05-02 Assembly 1 Protein homooligomer Homooligomer;Protein × 14 PDB declaration: tetradecameric(14) Consistent with protein count
Chain A 58–277(220 aa)
Chain B 58–277(220 aa)
Chain C 58–277(220 aa)
Chain D 58–277(220 aa)
Chain E 58–277(220 aa)
Chain F 58–277(220 aa)
Chain G 58–277(220 aa)
Not recorded OY9 3-({3-[(4-chlorophenyl)methyl]-4-oxo-3,5,7,8-tetrahydropyrido[4,3-d]pyrimidin-6(4H)-yl}methyl)benzonitrile × 14 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate, 5% PEG 4000
Resolution 3.24 Å R-free 0.261
7UW0 Crystal structure of human ClpP protease in complex with TR-133 Deposited 2022-05-02 Assembly 1 Protein homooligomer Homooligomer;Protein × 14 PDB declaration: tetradecameric(14) Consistent with protein count
Chain A 58–277(220 aa)
Chain B 58–277(220 aa)
Chain C 58–277(220 aa)
Chain D 58–277(220 aa)
Chain E 58–277(220 aa)
Chain F 58–277(220 aa)
Chain G 58–277(220 aa)
Not recorded P4I 3-({3-[(4-bromophenyl)methyl]-4-oxo-3,5,7,8-tetrahydropyrido[4,3-d]pyrimidin-6(4H)-yl}methyl)benzonitrile × 14 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 sodium acetate, pH 4.6 to 5.2, 5% PEG 4000
Resolution 2.80 Å R-free 0.309
7VP9 Crystal structure of human ClpP in complex with ZG111 Deposited 2021-10-15 Assembly 1 Protein homooligomer Homooligomer;Protein × 14 PDB declaration: tetradecameric(14) Consistent with protein count
Chain A 57–277(221 aa)
Chain B 57–277(221 aa)
Chain C 57–277(221 aa)
Chain D 57–277(221 aa)
Chain E 57–277(221 aa)
Chain F 57–277(221 aa)
Chain G 57–277(221 aa)
Chain H 57–277(221 aa)
Chain I 57–277(221 aa)
Chain J 57–277(221 aa)
Chain K 57–277(221 aa)
Chain L 57–277(221 aa)
Chain M 57–277(221 aa)
Chain N 57–277(221 aa)
Not recorded 7SR (6S,9aS)-N-[(4-bromophenyl)methyl]-6-[(2S)-butan-2-yl]-8-(naphthalen-1-ylmethyl)-4,7-bis(oxidanylidene)-3,6,9,9a-tetrahydro-2H-pyrazino[1,2-a]pyrimidine-1-carboxamide × 14 MG MAGNESIUM ION × 14 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 7.5;289 K;0.2M sodium bromide, 20% (w/v) polyethylene glycol 3350
Resolution 2.55 Å R-free 0.232
7WH5 Crystal structure of human ClpP in complex with ZG180 Deposited 2021-12-29 Assembly 1 Protein homooligomer Homooligomer;Protein × 14 PDB declaration: tetradecameric(14) Consistent with protein count
Chain A 57–277(221 aa)
Chain B 57–277(221 aa)
Chain C 57–277(221 aa)
Chain D 57–277(221 aa)
Chain E 57–277(221 aa)
Chain F 57–277(221 aa)
Chain G 57–277(221 aa)
Chain H 57–277(221 aa)
Chain I 57–277(221 aa)
Chain J 57–277(221 aa)
Chain K 57–277(221 aa)
Chain L 57–277(221 aa)
Chain M 57–277(221 aa)
Chain N 57–277(221 aa)
Not recorded 9DF (6S,9aS)-6-[(2S)-butan-2-yl]-8-(naphthalen-1-ylmethyl)-4,7-bis(oxidanylidene)-N-[4,4,4-tris(fluoranyl)butyl]-3,6,9,9a-tetrahydro-2H-pyrazino[1,2-a]pyrimidine-1-carboxamide × 14 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 7.5;289 K;0.2M Sodium malonate pH 5.0, 20% w/v Polyethylene glycol 3350
Resolution 2.13 Å R-free 0.249
8HGK Crystal structure of human ClpP in complex with ZK53 Deposited 2022-11-14 Assembly 1 Protein homooligomer Homooligomer;Protein × 14 PDB declaration: tetradecameric(14) Consistent with protein count
Chain A 57–277(221 aa)
Chain B 57–277(221 aa)
Chain C 57–277(221 aa)
Chain D 57–277(221 aa)
Chain E 57–277(221 aa)
Chain F 57–277(221 aa)
Chain G 57–277(221 aa)
Chain H 57–277(221 aa)
Chain I 57–277(221 aa)
Chain J 57–277(221 aa)
Chain K 57–277(221 aa)
Chain L 57–277(221 aa)
Chain M 57–277(221 aa)
Chain N 57–277(221 aa)
Not recorded ZLL 4-[[3,5-bis(fluoranyl)phenyl]methyl]-N-[(4-bromophenyl)methyl]piperazine-1-carboxamide × 14 MG MAGNESIUM ION × 5 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;289 K;0.2M Magnesium acetate tetrahydrate, 20% w/v Polyethylene glycol 3350, pH7.9
Resolution 1.90 Å R-free 0.221
8I7X Crystal structure of human ClpP in complex with ZG36 Deposited 2023-02-02 Assembly 1 Protein homooligomer Homooligomer;Protein × 14 PDB declaration: tetradecameric(14) Consistent with protein count
Chain A 57–277(221 aa)
Chain B 57–277(221 aa)
Chain C 57–277(221 aa)
Chain D 57–277(221 aa)
Chain E 57–277(221 aa)
Chain F 57–277(221 aa)
Chain G 57–277(221 aa)
Chain H 57–277(221 aa)
Chain I 57–277(221 aa)
Chain J 57–277(221 aa)
Chain K 57–277(221 aa)
Chain L 57–277(221 aa)
Chain M 57–277(221 aa)
Chain N 57–277(221 aa)
Not recorded OSR (6S,9aS)-N-[(4-bromophenyl)methyl]-6-[(2S)-butan-2-yl]-8-[(4-methoxynaphthalen-1-yl)methyl]-4,7-bis(oxidanylidene)-3,6,9,9a-tetrahydro-2H-pyrazino[1,2-a]pyrimidine-1-carboxamide × 14 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;289 K;0.2M sodium bromide, 20% (w/v) polyethylene glycol 3350
Resolution 1.99 Å R-free 0.260
8W7C Activation of mitochondrial Caseinolytic Protease P (ClpP) induces selective cancer cell lethality Deposited 2023-08-30 Assembly 1 Protein homooligomer Homooligomer;Protein × 14 PDB declaration: tetradecameric(14) Consistent with protein count
Chain A 58–277(220 aa)
Chain B 58–277(220 aa)
Chain C 58–277(220 aa)
Chain D 58–277(220 aa)
Chain E 58–277(220 aa)
Chain F 58–277(220 aa)
Chain G 58–277(220 aa)
Not recorded R89 11-[(3-chlorophenyl)methyl]-7-[[4-(trifluoromethyl)phenyl]methyl]-2,5,7,11-tetrazatricyclo[7.4.0.0^{2,6}]trideca-1(9),3,5-trien-8-one × 14 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6;289 K;200 mM KCl, 100 mM MES, 12%PEG4000
Resolution 3.00 Å R-free 0.260
8W7E Design, synthesis and biological evaluations of novel small molecular hyper-activators of human caseinolytic peptidase P (hClpP) Deposited 2023-08-30 Assembly 1 Protein homooligomer Homooligomer;Protein × 14 PDB declaration: tetradecameric(14) Consistent with protein count
Chain A 58–277(220 aa)
Chain B 58–277(220 aa)
Chain C 58–277(220 aa)
Chain D 58–277(220 aa)
Chain E 58–277(220 aa)
Chain F 58–277(220 aa)
Chain G 58–277(220 aa)
Chain H 58–277(220 aa)
Chain I 58–277(220 aa)
Chain J 58–277(220 aa)
Chain K 58–277(220 aa)
Chain L 58–277(220 aa)
Chain M 58–277(220 aa)
Chain N 58–277(220 aa)
Not recorded 9I3 3-[(3-chlorophenyl)methyl]-6-[(4-chlorophenyl)methyl]-2,4-dihydro-1H-pyrido[2,3-c][2,7]naphthyridin-5-one × 14 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6;289 K;6% (w/v) PEG 3350, 200 mM KCl, and 100 mM NaAc (pH 6.0)
Resolution 2.80 Å R-free 0.274
8WUZ Development of 2-imino-2,3,5,6,7,8-hexahydropyrido[4,3-d]pyrimidin-4(1H)-one derivatives as human caseinolytic peptidase P (hClpP) activators Deposited 2023-10-22 Assembly 1 Protein homooligomer Homooligomer;Protein × 14 PDB declaration: tetradecameric(14) Consistent with protein count
Chain A 58–277(220 aa)
Chain B 58–277(220 aa)
Chain C 58–277(220 aa)
Chain D 58–277(220 aa)
Chain E 58–277(220 aa)
Chain F 58–277(220 aa)
Chain G 58–277(220 aa)
Not recorded XFU 5-[(3-fluorophenyl)methyl]-9-[[4-(trifluoromethyl)phenyl]methyl]-1,5,9,11-tetrazatricyclo[8.4.0.0^{2,7}]tetradeca-2(7),10-dien-8-one × 14 BR BROMIDE ION × 16 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;298.15 K;0.2 M NaBr, 16% PEG 3350
Resolution 2.90 Å R-free 0.276
8YLB Cocrystal structures of agonists compound 1 with HsClpP Deposited 2024-03-06 Assembly 1 Protein homooligomer Homooligomer;Protein × 14 PDB declaration: tetradecameric(14) Consistent with protein count
Chain A 58–277(220 aa)
Chain B 58–277(220 aa)
Chain C 58–277(220 aa)
Chain D 58–277(220 aa)
Chain E 58–277(220 aa)
Chain F 58–277(220 aa)
Chain G 58–277(220 aa)
Chain H 58–277(220 aa)
Chain I 58–277(220 aa)
Chain J 58–277(220 aa)
Chain K 58–277(220 aa)
Chain L 58–277(220 aa)
Chain M 58–277(220 aa)
Chain N 58–277(220 aa)
Not recorded A1LZA 5-[(2-methylphenyl)methyl]-11-(phenylmethyl)-2,5,7,11-tetrazatricyclo[7.4.0.0^{2,6}]trideca-1(9),6-dien-8-one × 14 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8;291 K;1.6 M Li2SO4 and 0.1 M Tris, pH 8.0
Resolution 2.15 Å R-free 0.260
8YPA Human mitochondrial ClpP in complex with TR89 Deposited 2024-03-16 Assembly 1 Protein homooligomer Homooligomer;Protein × 7 PDB declaration: heptameric(7) Consistent with protein count
Chain A 58–277(220 aa)
Chain B 58–277(220 aa)
Chain C 58–277(220 aa)
Chain D 58–277(220 aa)
Chain E 58–277(220 aa)
Chain F 58–277(220 aa)
Chain G 58–277(220 aa)
Not recorded A1LZN (6~{R})-2-[[3,5-bis(fluoranyl)phenyl]methyl]-6-(hydroxymethyl)-5-[[4-(trifluoromethyl)phenyl]methyl]-7,8-dihydro-6~{H}-pyrazolo[1,5-a][1,4]diazepin-4-one × 7 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.2;289.15 K;0.1 M sodium acetate ph 6.2, 8% PEG 4000
Resolution 2.67 Å R-free 0.258
9DKV Human mitochondrial ClpP in Apo state Deposited 2024-09-10 Assembly 1 Protein homooligomer Homooligomer;Protein × 14 PDB declaration: 14-meric(14) Consistent with protein count
Chain A 58–277(220 aa)
Chain B 58–277(220 aa)
Chain C 58–277(220 aa)
Chain D 58–277(220 aa)
Chain E 58–277(220 aa)
Chain F 58–277(220 aa)
Chain G 58–277(220 aa)
Chain H 58–277(220 aa)
Chain I 58–277(220 aa)
Chain J 58–277(220 aa)
Chain K 58–277(220 aa)
Chain L 58–277(220 aa)
Chain M 58–277(220 aa)
Chain N 58–277(220 aa)
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.81 Å
9DKW Human mitochondrial ClpP in complex with Bortezomib Deposited 2024-09-10 Assembly 1 Protein homooligomer Homooligomer;Protein × 14 PDB declaration: 14-meric(14) Consistent with protein count
Chain A 58–277(220 aa)
Chain B 58–277(220 aa)
Chain C 58–277(220 aa)
Chain D 58–277(220 aa)
Chain E 58–277(220 aa)
Chain F 58–277(220 aa)
Chain G 58–277(220 aa)
Chain H 58–277(220 aa)
Chain I 58–277(220 aa)
Chain J 58–277(220 aa)
Chain K 58–277(220 aa)
Chain L 58–277(220 aa)
Chain M 58–277(220 aa)
Chain N 58–277(220 aa)
Not recorded BO2 N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE × 14 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.49 Å
9DQK human ClpP - Apo - A192E / E196R Deposited 2024-09-24 Assembly 1 Protein homooligomer Homooligomer;Protein × 14 PDB declaration: 14-meric(14) Consistent with protein count
Chain A 1–277(277 aa)
Chain B 1–277(277 aa)
Chain C 1–277(277 aa)
Chain D 1–277(277 aa)
Chain E 1–277(277 aa)
Chain F 1–277(277 aa)
Chain G 1–277(277 aa)
Chain H 1–277(277 aa)
Chain I 1–277(277 aa)
Chain J 1–277(277 aa)
Chain K 1–277(277 aa)
Chain L 1–277(277 aa)
Chain M 1–277(277 aa)
Chain N 1–277(277 aa)
Mutation:A192E, E196R Mutation:A192E, E196R Mutation:A192E, E196R Mutation:A192E, E196R Mutation:A192E, E196R Mutation:A192E, E196R Mutation:A192E, E196R Mutation:A192E, E196R Mutation:A192E, E196R Mutation:A192E, E196R Mutation:A192E, E196R Mutation:A192E, E196R Mutation:A192E, E196R Mutation:A192E, E196R CL CHLORIDE ION × 14 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;295 K;200 mM potassium acetate, 35% (v/v) pentaerythritol propoxylate (5/4 PO/OH)
Resolution 2.75 Å R-free 0.250
9DQL human ClpP - Bortezomib - A192E / E196R Deposited 2024-09-24 Assembly 1 Protein homooligomer Homooligomer;Protein × 14 PDB declaration: 14-meric(14) Consistent with protein count
Chain A 1–277(277 aa)
Chain B 1–277(277 aa)
Chain C 1–277(277 aa)
Chain D 1–277(277 aa)
Chain E 1–277(277 aa)
Chain F 1–277(277 aa)
Chain G 1–277(277 aa)
Chain H 1–277(277 aa)
Chain I 1–277(277 aa)
Chain J 1–277(277 aa)
Chain K 1–277(277 aa)
Chain L 1–277(277 aa)
Chain M 1–277(277 aa)
Chain N 1–277(277 aa)
Mutation:A192E, E196R Mutation:A192E, E196R Mutation:A192E, E196R Mutation:A192E, E196R Mutation:A192E, E196R Mutation:A192E, E196R Mutation:A192E, E196R Mutation:A192E, E196R Mutation:A192E, E196R Mutation:A192E, E196R Mutation:A192E, E196R Mutation:A192E, E196R Mutation:A192E, E196R Mutation:A192E, E196R BO2 N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE × 14 CL CHLORIDE ION × 9 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;295 K;200 mM potassium acetate, 35% (v/v) pentaerythritol propoxylate (5/4 PO/OH)
Resolution 3.20 Å R-free 0.237
9DW0 Human ClpX-bound ClpP Deposited 2024-10-08 Assembly 1 Protein homooligomer Homooligomer;Protein × 14 PDB declaration: tetradecameric(14) Consistent with protein count
Chain H 58–249(192 aa)
Chain I 58–249(192 aa)
Chain J 58–249(192 aa)
Chain K 58–249(192 aa)
Chain L 58–249(192 aa)
Chain M 58–249(192 aa)
Chain N 58–249(192 aa)
Chain O 58–249(192 aa)
Chain P 58–249(192 aa)
Chain Q 58–249(192 aa)
Chain R 58–249(192 aa)
Chain S 58–249(192 aa)
Chain T 58–249(192 aa)
Chain U 58–249(192 aa)
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions Cryogen ETHANE;The sample was prepared using manual blot-and-plunge freezing method in cold room (4 celsius)
Resolution 2.80 Å
9DW1 Human mitochondrial ClpP protease Deposited 2024-10-08 Assembly 1 Protein homooligomer Homooligomer;Protein × 7 PDB declaration: heptameric(7) Consistent with protein count
Chain H 58–277(220 aa)
Chain I 58–277(220 aa)
Chain J 58–277(220 aa)
Chain K 58–277(220 aa)
Chain L 58–277(220 aa)
Chain M 58–277(220 aa)
Chain N 58–277(220 aa)
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions Cryogen ETHANE;The sample was prepared using manual blot-and-plunge freezing method in cold room (4 celsius)
Resolution 3.40 Å
9DW3 Human mitochondrial ClpP in complex with Bortezomib Deposited 2024-10-08 Assembly 1 Protein homooligomer Homooligomer;Protein × 14 PDB declaration: tetradecameric(14) Consistent with protein count
Chain A 58–277(220 aa)
Chain B 58–277(220 aa)
Chain C 58–277(220 aa)
Chain D 58–277(220 aa)
Chain E 58–277(220 aa)
Chain F 58–277(220 aa)
Chain G 58–277(220 aa)
Chain H 58–277(220 aa)
Chain I 58–277(220 aa)
Chain J 58–277(220 aa)
Chain K 58–277(220 aa)
Chain L 58–277(220 aa)
Chain M 58–277(220 aa)
Chain N 58–277(220 aa)
Not recorded BO2 N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE × 14 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions Cryogen ETHANE;The sample was prepared using manual blot-and-plunge freezing method in cold room (4 celsius)
Resolution 2.40 Å
9KUF Cryo-EM structure of HsClpP bound to CLPP-2068 Deposited 2024-12-03 Assembly 1 Protein homooligomer Homooligomer;Protein × 14 PDB declaration: tetradecameric(14) Consistent with protein count
Chain A 59–277(219 aa)
Chain B 59–277(219 aa)
Chain C 59–277(219 aa)
Chain D 59–277(219 aa)
Chain E 59–277(219 aa)
Chain F 59–277(219 aa)
Chain G 59–277(219 aa)
Chain H 59–277(219 aa)
Chain I 59–277(219 aa)
Chain J 59–277(219 aa)
Chain K 59–277(219 aa)
Chain L 59–277(219 aa)
Chain M 59–277(219 aa)
Chain N 59–277(219 aa)
Not recorded A1EG3 3-[[(7~{R})-2-[(4-bromophenyl)methylamino]-7-methyl-4-oxidanylidene-3,5,7,8-tetrahydropyrido[4,3-d]pyrimidin-6-yl]methyl]benzenecarbonitrile × 14 ELECTRON MICROSCOPY
cryo-EM buffer pH 8;30 mM Tris-HCl (pH 8.0), 150 mM NaCl and 1 mM DTT
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.45 Å
9PB1 Human ClpP initial assembly Deposited 2025-06-26 Assembly 1 Protein homooligomer Homooligomer;Protein × 7 PDB declaration: heptameric(7) Consistent with protein count
Chain H 58–277(220 aa)
Chain I 58–277(220 aa)
Chain J 58–277(220 aa)
Chain K 58–277(220 aa)
Chain L 58–277(220 aa)
Chain M 58–277(220 aa)
Chain N 58–277(220 aa)
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions Cryogen ETHANE;The sample was prepared using manual blot-and-plunge freezing method in cold room (4 degrees Celsius).
Resolution 3.70 Å
9WAS Human mitochondrial ClpP in complex with LZL25 Deposited 2025-08-12 Assembly 1 Protein homooligomer Homooligomer;Protein × 14 PDB declaration: tetradecameric(14) Consistent with protein count
Chain A 58–250(193 aa)
Chain B 58–250(193 aa)
Chain C 58–250(193 aa)
Chain D 58–250(193 aa)
Chain E 58–250(193 aa)
Chain F 58–250(193 aa)
Chain G 58–250(193 aa)
Not recorded A1EVT (3~{R})-7-[(4-fluorophenyl)methyl]-3-(2-methoxyethoxymethyl)-2-[[4-(trifluoromethyl)phenyl]methyl]-3,4-dihydroisoquinolin-1-one × 14 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;291 K;0.1M sodium acetate trihydrate pH4.6 8% w/v Polyethylene Glycol 4000
Resolution 3.52 Å R-free 0.247
9YKZ Un-crosslinked hClpP Deposited 2025-10-08 Assembly 1 Protein homooligomer Homooligomer;Protein × 7 PDB declaration: heptameric(7) Consistent with protein count
Chain H 1–277(277 aa)
Chain I 1–277(277 aa)
Chain J 1–277(277 aa)
Chain K 1–277(277 aa)
Chain L 1–277(277 aa)
Chain M 1–277(277 aa)
Chain N 1–277(277 aa)
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions Cryogen ETHANE;The sample was prepared using manual blot-and-plunge freezing method in cold room (4 degrees Celsius)
Resolution 3.50 Å